Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07841925 | A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07838974 | Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or Older | not yet recruiting | Phase 1 | 40 | University of Southern CaliforniaOTHER | 1 | Sep 24, 2026 |
| clinicaltrials |
| NCT07817901 | Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Combination Therapy With Pembrolizumab and Irinotecan in Patients With Metastatic or Recurrent Malignant Melanoma | not yet recruiting | Phase 1 / Phase 2 | 46 | Yonsei UniversityOTHER | 0 | Sep 14, 2026 | clinicaltrials |
| NCT05903937 | Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases(HAITILS-PHP) | not yet recruiting | Phase 1 | 6 | Vastra Gotaland RegionOTHER_GOV | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07183852 | Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma(GoTIL-01) | not yet recruiting | Phase 1 | 18 | Vastra Gotaland RegionOTHER_GOV | 0 | Sep 9, 2026 | clinicaltrials |
| NCT06739226 | Combination Immunotherapy Targeting Melanoma | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07414979 | Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma | not yet recruiting | Phase 1 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07747935 | Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma(Uveal Melanoma) | not yet recruiting | Phase 1 / Phase 2 | 30 | ReBio PharmaINDUSTRY | 0 | Aug 5, 2026 | clinicaltrials |
| NCT07631325 | Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma(MORALE-MM) | not yet recruiting | Phase 1 / Phase 2 | 28 | John KirkwoodOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07628894 | Circadian-Optimized Light Therapy for the Treatment of Patients With Advanced Melanoma Receiving Tumor-Infiltrating Lymphocyte Therapy | not yet recruiting | Phase 1 | 8 | City of Hope Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07615881 | Comparing Intravenous or Intradermal Administration of Anti-CTLA-4 in Combination With Anti-PD1 Treatment in Patients With Melanoma(IpiD) | not yet recruiting | Phase 1 / Phase 2 | 18 | Amsterdam UMC, location VUmcOTHER | 0 | May 29, 2026 | clinicaltrials |
| NCT07581509 | Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma | not yet recruiting | Phase 1 | 138 | Biocon Biologics UK PLCINDUSTRY | 0 | May 14, 2026 | clinicaltrials |
| NCT07444606 | Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases | not yet recruiting | Phase 1 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07320222 | CARE-Melanoma Trial(CARE-Melanoma) | not yet recruiting | Phase 1 | 30 | McMaster UniversityOTHER | 0 | Jan 6, 2026 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT07107178 | A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 6, 2025 | clinicaltrials |
| NCT07040436 | Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1(REVERT) | not yet recruiting | Phase 1 / Phase 2 | 41 | Oncodesign Precision MedicineINDUSTRY | 0 | Jun 27, 2025 | clinicaltrials |
| NCT05275374 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation(ENHANCE) | not yet recruiting | Phase 1 / Phase 2 | 221 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 0 | Apr 10, 2025 | clinicaltrials |
| NCT05539118 | Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma | not yet recruiting | Phase 1 / Phase 2 | 48 | Xijing HospitalOTHER | 1 | Sep 14, 2022 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials